Biosimilar Market: The Future for the Generic Pharmaceuticals Industry

PUNE, India, March 13, 2020 /PRNewswire/ -- With some of the world's best-known biologics continuing to face patent expiration in the coming years, the biosimilars market is set for continued growth. Infinium Global Research has recently published a global report on "Biosimilar Market (Product - Human Growth Hormones, Monoclonal Antibodies, Insulin, Peptides, Erythropoietin, and Other Products; Application - Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, and Other Applications): Global Industry Analysis, Trends, Size, Share and Forecasts to 2025". The reported study estimated the market for biosimilar will reach up to 55.19 Billion by 2025, with a Compound annual growth rate of 35.12%, in the forecast period (2019-2025).  

Infinium Global Research Logo

Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/6039 

A biosimilar is a biologic product that is highly identical to the original biologic product, known as a reference product. Biosimilar products are large and usually complex molecules produced from living organisms and are keenly monitored to ensure consistent quality. In biosimilar products, most minor differences in clinically inactive components are permissible. On basis of studies such as pharmacokinetics, pharmacodynamics, and immunogenicity assessment as well as additional clinical studies it is shown that biosimilars have no clinically meaningful differences in safety, purity or potency as compared to the reference product. Globally due to the increasing number of chronic diseases such as cancer, diabetes, autoimmune diseases, growth hormone deficiency, hematological diseases, there is a rise in demand for biosimilar products and tends to continue the trend in the forecast period.  

Patent Expiration of More Than USD 70 Billion Biologicals is Expected to Boost the Biosimilar Market 

The most important key factor driving the biosimilar market is the patent cliff of prime biological drugs. Patent expiry permits competitors as well as small manufacturing companies to produce biosimilars which in turn boosts the overall biosimilar market, the growth is largely driven by approximately USD 80 Billion worth of biologics going off patent by 2020. Additional factors contributing to fueling the biosimilar market are the low cost of biosimilars as compared to the approved referenced product, increase in age-related disorder as a result of growing geriatric population and positive outcomes in clinical trial studies. In addition to this rising awareness promoted for use of biosimilars by the government as well as private organizations propel the biosimilar market.  

High Research and Manufacturing Cost Can Hinder the Market Growth

High cost associated with manufacturing as well as research and development of biosimilar, easy accessibility of generic drugs at reasonable price and consumers increased inclination towards original product hampers the growth of the market. In addition to this, stringent regulatory guidelines for approval of biosimilar affects the growth of the market as the biosimilar must show similarity with the reference product in terms of safety and efficacy. Reduction in cost through innovation and strategic collaboration among manufactures ensures to accelerate the growth of the biosimilar market during the forecast period.

Insulin and Monoclonal Antibodies Expected to Hold Major Share of the Market in the Forecast Period

The global biosimilar market is segmented by product and application. Based on the product, the market is segmented as human growth hormones, monoclonal antibodies, insulin, peptides, erythropoietin, and others. Based on the application, the market is segmented as oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others. The oncology segment dominates the market revenue as a result of an increase in awareness and adoption of cancer drugs in the treatment.       

Asia Pacific is Expected to Register High Growth in the Forecast Period with the More Approved Drugs in the Market

Based on geographical analysis, the global biosimilar market is categorized into North America, Europe, Asia Pacific and Rest of the World. Europe holds the highest share in the market owing to supportive government regulations as well as an increase in biosimilar acceptance that they are equivalent to patented drugs. In 2017, the European market was approximately $2.5million with 36 biosimilars being approved by May 2018. North America holds the second most share in the market and is expected to increase during the forecast period due to initiatives taken for use of biosimilars as well as in research and development. Asia Pacific region is anticipated to show substantial growth in the forecast period, with more than 50 approved products, minimal complexity of regulatory guidelines, and adequately less manufacturing cost providing a suitable environment for the growth of the market.  

Need Assistance? Send an Enquiry@ https://www.infiniumglobalresearch.com/reports/enquiry/6039 

Global Biosimilar Industry Coverage

Chapter - 1     Preface

  • Report Description
  • Research Methods
  • Research Approaches

Chapter - 2     Executive Summary

  • Biosimilar Market Highlights
  • Biosimilar Market Projection
  • Biosimilar Market Regional Highlights

Chapter - 3     Global Biosimilar Market Overview

  • Introduction
  • Market Dynamics
  • Porter's Five Forces Analysis
  • IGR-Growth Matrix Analysis
  • Value Chain Analysis of Biosimilar Market

Chapter - 4     Biosimilar Market Macro Indicator Analysis

Chapter - 5     Global Biosimilar Market by Product

  • Human Growth Hormones
  • Monoclonal Antibodies
  • Insulin
  • Peptides
  • Erythropoietin
  • Other Products

Chapter - 6     Global Biosimilar Market by Application

  • Oncology
  • Chronic and Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Applications

Chapter - 7     Global Biosimilar Market by Region 2019-2025

  • North America
  • Europe
  • Asia-Pacific
  • RoW

Chapter - 8     Company Profiles and Competitive Landscape

  • Allergan plc
  • BIOCAD
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc, Coherus BioSciences, Inc
  • Dr. Reddy's Laboratories Ltd
  • Genor BioPharma Co. Ltd
  • Intas Pharmaceuticals Limited
  • Novartis AG

Browse in-depth TOC on "Biosimilar Market"

About Us

Infinium Global Research is a business consulting and market research firm; a group of experts that caters to fulfilling business and market research needs of leading companies in various industry verticals and business segments. The company also serves government bodies, institutes and non-profit/non-government organizations to meet their knowledge and information needs.

Through our information services and solutions, we assist our clients to improve their performance and assess the market conditions to achieve their organizational goals. Our team of experts and analysts are engaged in continuously monitoring and assessing the market conditions to provide the knowledge support to our clients. To help our clients and to stay updated with the advances and inventions in technology, business processes, regulations and environment, Infinium often conducts regular meets with industry experts and opinion leaders. Our key opinion leaders are involved in monitoring and assessing the progress in the business environment, so as to offer the best opinion to our clients.

Contact:

Mr. Shrikant Athavale
Infinium Global Research
Office No. 103 and 104,
Suratwala Mark Plazzo,
Hinjawadi, Pune,
Maharashtra,
Pin- 411057.
USA: 1-888-500-3114
Email: info@infiniumglobalresearch.com 
Research Insight: 
https://www.infiniumglobalresearch.com/healthcare-medical-devices/global-biosimilar-market 
Visit Our Web Site: https://www.infiniumglobalresearch.com

Cision View original content:http://www.prnewswire.com/news-releases/biosimilar-market-the-future-for-the-generic-pharmaceuticals-industry-301022817.html

SOURCE Infinium Global Research

News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.